Halozyme to Present at Upcoming Investor Conferences
Halozyme Therapeutics (NASDAQ: HALO) has announced its participation in three upcoming investor conferences in September 2024. The company's leadership, including Dr. Helen Torley, President and CEO, and Tram Bui, VP of Investor Relations, will be presenting and hosting investor meetings at these events.
The conferences include the 2024 Wells Fargo Healthcare Conference in Boston on September 4, the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 5, and the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 10. Presentations at Wells Fargo and H.C. Wainwright will be in a fireside chat format, while the Morgan Stanley event will feature 1x1 meetings only.
Live audio webcasts of the presentations will be available on Halozyme's website, with replays accessible for 90 days after each conference.
Halozyme Therapeutics (NASDAQ: HALO) ha annunciato la sua partecipazione a tre conferenze per investitori che si terranno a settembre 2024. I leader dell'azienda, tra cui Dr. Helen Torley, Presidente e CEO, e Tram Bui, VP delle Relazioni con gli Investitori, presenteranno e guideranno incontri con gli investitori durante questi eventi.
Le conferenze includono il 2024 Wells Fargo Healthcare Conference a Boston il 4 settembre, il Morgan Stanley 22nd Annual Global Healthcare Conference a New York il 5 settembre e il H.C. Wainwright 26th Annual Global Investment Conference a New York il 10 settembre. Le presentazioni al Wells Fargo e all'H.C. Wainwright saranno in formato conversazione informale, mentre l'evento di Morgan Stanley prevederà solo incontri one-to-one.
Le trasmissioni audio in diretta delle presentazioni saranno disponibili sul sito web di Halozyme, con repliche accessibili per 90 giorni dopo ciascuna conferenza.
Halozyme Therapeutics (NASDAQ: HALO) ha anunciado su participación en tres próximas conferencias para inversores en septiembre de 2024. El liderazgo de la empresa, incluyendo a Dr. Helen Torley, Presidenta y CEO, y Tram Bui, VP de Relaciones con Inversores, estará presentando y organizando reuniones con inversores en estos eventos.
Las conferencias incluyen la 2024 Wells Fargo Healthcare Conference en Boston el 4 de septiembre, la Morgan Stanley 22nd Annual Global Healthcare Conference en Nueva York el 5 de septiembre, y la H.C. Wainwright 26th Annual Global Investment Conference en Nueva York el 10 de septiembre. Las presentaciones en Wells Fargo y H.C. Wainwright serán en formato de charla informal, mientras que el evento de Morgan Stanley solo contará con reuniones uno a uno.
Las transmisiones de audio en vivo de las presentaciones estarán disponibles en el sitio web de Halozyme, con repeticiones accesibles durante 90 días después de cada conferencia.
Halozyme Therapeutics (NASDAQ: HALO)는 2024년 9월에 있을 세 가지 투자자 회의에 참여한다고 발표했습니다. 이 회사의 리더십에는 Dr. Helen Torley 사장 겸 CEO와 Tram Bui 투자자 관계 VP가 포함되어 있으며, 이들 모두가 이 행사에서 발표 및 투자자 회의를 진행할 예정입니다.
회의는 9월 4일 보스턴에서 열리는 2024 Wells Fargo Healthcare Conference, 9월 5일 뉴욕에서 열리는 Morgan Stanley 22nd Annual Global Healthcare Conference, 9월 10일 뉴욕에서 열리는 H.C. Wainwright 26th Annual Global Investment Conference를 포함합니다. Wells Fargo와 H.C. Wainwright에서의 발표는 편안한 대화 형식으로 진행되며, Morgan Stanley 이벤트는 1 대 1 미팅으로만 진행됩니다.
발표의 실시간 오디오 웹캐스트는 Halozyme 웹사이트에서 제공될 예정이며, 각 회의 후 90일 동안 다시 볼 수 있도록 제공됩니다.
Halozyme Therapeutics (NASDAQ: HALO) a annoncé sa participation à trois prochaines conférences pour investisseurs en septembre 2024. La direction de l'entreprise, notamment Dr. Helen Torley, Présidente et CEO, et Tram Bui, VP des Relations Investisseurs, présentera et organisera des réunions avec les investisseurs lors de ces événements.
Les conférences comprennent la 2024 Wells Fargo Healthcare Conference à Boston le 4 septembre, la Morgan Stanley 22nd Annual Global Healthcare Conference à New York le 5 septembre, et la H.C. Wainwright 26th Annual Global Investment Conference à New York le 10 septembre. Les présentations lors de Wells Fargo et H.C. Wainwright se dérouleront sous forme de discussions informelles, tandis que l'événement de Morgan Stanley proposera uniquement des réunions individuelles.
Des webcasts audio en direct des présentations seront disponibles sur le site de Halozyme, avec des rediffusions accessibles pendant 90 jours après chaque conférence.
Halozyme Therapeutics (NASDAQ: HALO) hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen im September 2024 bekanntgegeben. Die Unternehmensleitung, einschließlich Dr. Helen Torley, Präsidentin und CEO, sowie Tram Bui, VP für Investor Relations, wird bei diesen Veranstaltungen präsentieren und Investoren-Meetings abhalten.
Die Konferenzen umfassen die 2024 Wells Fargo Healthcare Conference in Boston am 4. September, die Morgan Stanley 22nd Annual Global Healthcare Conference in New York am 5. September und die H.C. Wainwright 26th Annual Global Investment Conference in New York am 10. September. Die Präsentationen bei Wells Fargo und H.C. Wainwright werden im Format eines informellen Gesprächs stattfinden, während die Morgan Stanley-Veranstaltung ausschließlich 1x1-Meetings bieten wird.
Live-Audio-Webcasts der Präsentationen werden auf der Website von Halozyme verfügbar sein, mit Wiederholungen, die 90 Tage nach jeder Konferenz zugänglich sind.
- None.
- None.
Details of the presentations are as follow:
Event: | 2024 Wells Fargo Healthcare Conference | |||
Format: | Fireside Chat and 1x1 Meetings | |||
Presentation Date: | Wednesday, September 4, 2024 | |||
Presentation Time: | 12:00 p.m. PT / 3:00 p.m. ET | |||
Location: | ||||
Event: | Morgan Stanley 22nd Annual Global Healthcare Conference | ||||
Format: | 1x1 Meetings | ||||
Date: | Thursday, September 5, 2024 | ||||
Location: | |||||
Event: | H.C. Wainwright 26th Annual Global Investment Conference |
Format: | Fireside Chat and 1x1 Meetings |
Presentation Date: | Tuesday, September 10, 2024 |
Presentation Time: | 7:00 a.m. PT / 10:00 a.m. ET |
Location: |
A live audio webcast of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcast will be available for 90 days following the conference.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in eight commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-present-at-upcoming-investor-conferences-302232554.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When is Halozyme (HALO) presenting at the Wells Fargo Healthcare Conference in 2024?
Which investor conferences is Halozyme (HALO) attending in September 2024?
Who will be representing Halozyme (HALO) at the upcoming investor conferences?
Where can investors access the live audio webcasts of Halozyme's (HALO) presentations?
How long will the replays of Halozyme's (HALO) presentation webcasts be available?
